Bkemv is approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria and for those with atypical hemolytic uremic syndrome, according to a May 28 news release from the FDA.
Bkemv is the 53rd approved biosimilar in the U.S.
Next Up in Pharmacy
-
Health systems across the U.S. are implementing various strategies to manage pharmaceutical expenses while maintaining high care standards. Below are…
-
Charlottesville, Va.-based UVA Health is building a central pharmacy service center designed to streamline operations, improve patient access and expand…
Comments are closed.